ARTICLE | Emerging Company Profile
Targeted disruption
PEP-Therapy's peptides block specific protein-protein interactions
November 2, 2015 8:00 AM UTC
PEP-Therapy S.A.S. is developing fusion peptides for cancer that block specific intracellular protein-protein interactions, which could be safer than broad inhibitors of the same proteins.
The company's fusion peptides comprise an optimized cell-penetrating peptide that shuttles a short interfering peptide into the cell...